Unexpected MR-T1 enhancement of endocrine liver metastases with mangafodipir

Mathieu, Didier; Coffin, C. M.; Kobeiter, Hicham; Caseiro-Alves, Filipe; Mahfouz, Ahmed; Rahmouni, Alain; Diche, Thierry

doi:10.1002/(sici)1522-2586(199908)10:2<193::aid-jmri13>3.0.co;2-2

Cited by 19 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, differentiation between cysts/hemangiomas and metastases is primarily based on T2w pulse sequences. Very rarely, enhancement of neuroendocrine tumour metastases has been described [48]. The pathophysiology of enhancement of these metastases is not yet clear, but may be related to the increased metabolism of these tumours.…”

Section: Metastasesmentioning

confidence: 99%

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications

2004

View full text Add to dashboard Cite

Hepatobiliary contrast agents with uptake into hepatocytes followed by variable biliary excretion represent a unique class of cell-specific MR contrast agents. Two hepatobiliary contrast agents, mangafodipir trisodium and gadobenate dimeglumine, are already clinically approved. A third hepatobiliary contrast agent, Gd-EOB-DTPA, is under consideration. The purpose of this review is to provide an overview on the properties, clinical development and application of these three hepatobiliary contrast agents. Bolus injectable paramagnetic hepatobiliary contrast agents combine established features of extracellular agents with the advantages of hepatocyte specificity. The detection and characterisation of focal liver disease appears to be improved compared to unenhanced MRI, MRI with unspecific contrast agents and contrast-enhanced CT. To decrease the total time spent by a patient in the MR scanner, it is advisable to administer the agent immediately after acquisition of unenhanced T1-w MRI. After infusion or bolus injection (with dynamic FS-T1-w 2D or 3D GRE) of the contrast agent, moderately and heavily T2w images are acquired. Post-contrast T1-w MRI is started upon completion of T2-w MRI for mangafodipir trisodium and Gd-EOB-DTPA as early as 20 min following injection, while gadobenate dimeglumine scans are obtained >60 min following injection. Post-contrast acquisition techniques with near isotropic 3D pulse sequences with fat saturation parallel the technical progress made by MSCT combined with an unparalleled improvement in tumour-liver contrast. The individual decision that hepatobiliary contrast agent one uses is partly based on personal preferences. No comparative studies have been conducted comparing the advantages or disadvantages of all three agents directly against each other.

show abstract

Section: Metastasesmentioning

confidence: 99%

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications

2004

View full text Add to dashboard Cite

show abstract

“…34 Other nonhepatocellular liver lesions, such as hemangiomas and cysts, also do not show an uptake of the contrast agent and the peripheral rim enhancement is rarely seen, because of their slow growth. 35 However, differentiation between cysts or hemangiomas and metastases is primarily based on T2-weighed pulse sequences, where the former lesions appear highly hyperintese. Enhancement of neuroendocrine tumor metastases has been described rarely.…”

Section: Characterization Of Liver Lesions Liver Metastasesmentioning

confidence: 99%

“…Enhancement of neuroendocrine tumor metastases has been described rarely. 35 The pathophysiology of enhancement of these metastases has not been clarified, but it may be related to the increased metabolism of these tumors.…”

Section: Characterization Of Liver Lesions Liver Metastasesmentioning

confidence: 99%

Mangafodipir trisodium: review of its use as an injectable contrast medium for magnetic resonance imaging

Regge¹,

Cirillo²,

Macera³

et al. 2009

RMI

View full text Add to dashboard Cite

Mangafodipir trisodium is a hepatobiliary contrast agent, taken up by the hepatocytes and largely excreted via the bile ducts. The agent increases the signal intensity of the normal liver, and to a lesser extent of the pancreas, adrenal glands, kidneys and myocardium, on T1-weighted imaging. The increase of the signal intensity on the T1 images allows better visualization of focal lesions, especially of those that are of non-hepatocitary origin such as metastases. For this reason the most important indication for the use of mangafodipir trisodium is in detecting liver metastases, especially when the information may influence therapeutic planning, which in many cases is surgical resection. New data show that this liver-specific contrast agent is accurate in detecting small lesions and in assessing the liver status following neoadjuvant chemotherapy, where other imaging techniques, such as CT and PET, fail. Other lesser indications for studies with mangafodipir trisodium are: in characterizing liver and pancreatic lesions; in identifying biliary leakage following bile duct and/or liver surgery; and possibly in the future in the assessment of the extent of myocardial damage.

show abstract

“…Contrast agents with hepato-specific properties have been shown to increase the sensitivity of MR imaging for the detection of focal hepatic lesions (12)(13)(14)(15), although the role of these agents in the characterization of focal lesions has yet to be fully elucidated. Gadobenate dimeglumine (Gd-BOPTA) (Multihance; Bracco Imaging, Milan, Italy) is a paramagnetic gadolinium-based contrast agent that, in common with other gadolinium agents, has a vascular-interstitial distribution in the first few minutes after injection.…”

Section: Gastrointestinal Imagingmentioning

confidence: 99%

Focal Nodular Hyperplasia: Morphologic and Functional Information from MR Imaging with Gadobenate Dimeglumine

Grazioli¹,

Morana²,

Federle³

et al. 2001

Radiology

141

View full text Add to dashboard Cite

show abstract

Unexpected MR-T1 enhancement of endocrine liver metastases with mangafodipir

Cited by 19 publications

References 13 publications

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications

Mangafodipir trisodium: review of its use as an injectable contrast medium for magnetic resonance imaging

Focal Nodular Hyperplasia: Morphologic and Functional Information from MR Imaging with Gadobenate Dimeglumine

Contact Info

Product

Resources

About